BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25211704)

  • 21. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site.
    Edler MC; Buey RM; Gussio R; Marcus AI; Vanderwal CD; Sorensen EJ; Díaz JF; Giannakakou P; Hamel E
    Biochemistry; 2005 Aug; 44(34):11525-38. PubMed ID: 16114889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
    More KN; Hong VS; Lee A; Park J; Kim S; Lee J
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
    Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
    Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guanylate-Binding Protein 1, an Interferon-Induced GTPase, Exerts an Antiviral Activity against Classical Swine Fever Virus Depending on Its GTPase Activity.
    Li LF; Yu J; Li Y; Wang J; Li S; Zhang L; Xia SL; Yang Q; Wang X; Yu S; Luo Y; Sun Y; Zhu Y; Munir M; Qiu HJ
    J Virol; 2016 May; 90(9):4412-4426. PubMed ID: 26889038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach.
    Verma K; Ramanathan K
    J Cell Biochem; 2015 Jul; 116(7):1318-24. PubMed ID: 25735511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
    Hu H; Wang X; Chan GK; Chang JH; Do S; Drummond J; Ebens A; Lee W; Ly J; Lyssikatos JP; Murray J; Moffat JG; Chao Q; Tsui V; Wallweber H; Kolesnikov A
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5258-64. PubMed ID: 26459208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
    Holder S; Zemskova M; Zhang C; Tabrizizad M; Bremer R; Neidigh JW; Lilly MB
    Mol Cancer Ther; 2007 Jan; 6(1):163-72. PubMed ID: 17218638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
    Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
    Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using insights into Pim1 structure to design new anticancer drugs.
    Schenone S; Tintori C; Botta M
    Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues.
    Ganesh T; Yang C; Norris A; Glass T; Bane S; Ravindra R; Banerjee A; Metaferia B; Thomas SL; Giannakakou P; Alcaraz AA; Lakdawala AS; Snyder JP; Kingston DG
    J Med Chem; 2007 Feb; 50(4):713-25. PubMed ID: 17263521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and docking study of pyridine and thieno[2,3-b] pyridine derivatives as anticancer PIM-1 kinase inhibitors.
    Abdelaziz ME; El-Miligy MMM; Fahmy SM; Mahran MA; Hazzaa AA
    Bioorg Chem; 2018 Oct; 80():674-692. PubMed ID: 30064079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
    Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
    Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer.
    Honkala AT; Tailor D; Malhotra SV
    Front Immunol; 2019; 10():3139. PubMed ID: 32117203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
    Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
    Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK
    Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
    Ling YH; Jiang JD; Holland JF; Perez-Soler R
    Mol Pharmacol; 2002 Sep; 62(3):529-38. PubMed ID: 12181429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.
    Liu Z; He W; Gao J; Luo J; Huang X; Gao C
    Oncotarget; 2015 Apr; 6(10):8019-35. PubMed ID: 25749522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.